Opipramol

Opipramol

SCHEMBL49841

OCCN1CCN(CCCN2c3ccccc3C=Cc3ccccc32)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 7/20 1.00
HTR1A P08908 6/20 1.00
HTR2A P28223 5/20 1.00
DRD3 P35462 5/20 1.00
ADRA2A P08913 4/20 1.00
ADRA2B P18089 4/20 1.00
ADRA2C P18825 4/20 1.00
SLC6A2 P23975 4/20 1.00
SLC6A4 P31645 4/20 1.00
ADRA1A P35348 4/20 1.00
HRH1 P35367 4/20 1.00
SLC6A3 Q01959 4/20 1.00
KCNH2 Q12809 4/20 1.00
DRD1 P21728 3/20 1.00
CHRM2 P08172 2/20 1.00
CHRM1 P11229 2/20 1.00
OPRM1 P35372 2/20 1.00
SIGMAR1 Q99720 2/20 1.00
HRH3 Q9Y5N1 2/20 1.00
PTGS1 P23219 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Opipramol SCHEMBL29414094 1.00 DRD2 (1.00) DRD2HTR1AHTR2ADRD3ADRA2A
Opipramol SCHEMBL30020862 0.98 CYP3A4 (1.00) DRD2HTR1AHTR2ADRD3ADRA2A
Opipramol SCHEMBL366168 0.98 CYP3A4 (1.00) DRD2HTR1AHTR2ADRD3ADRA2A
Opipramol SCHEMBL121971 0.98 CYP3A4 (1.00) DRD2HTR1AHTR2ADRD3ADRA2A
Opipramol SCHEMBL16416273 0.98 DRD2 (0.97) DRD2HTR1AHTR2ADRD3ADRA2A
Opipramol SCHEMBL21834066 0.97 DRD2 (0.94) DRD2HTR1AHTR2ADRD3ADRA2A
Opipramol SCHEMBL17609810 0.91 DRD2 (0.82) DRD2HTR1AHTR2ADRD3ADRA2A
Opipramol SCHEMBL17609820 0.91 HTR1A (0.82) DRD2HTR1AHTR2ADRD3ADRA2A
Opipramol SCHEMBL17609856 0.89 DRD2 (0.80) DRD2HTR1AHTR2ADRD3ADRA2A
Opipramol SCHEMBL28162240 0.89 DRD2 (0.80) DRD2HTR1AHTR2ADRD3ADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 5251 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260034065-A1 EXTENDED RELEASE PHARMACEUTICAL FORMULATION DOUGLAS PHARMACEUTICALS LTD (NZ) 2026-02-05 US claimed
US-20260001942-A1 TREATMENT OF HEADACHE DISORDERS AND/OR PSYCHIATRIC SYMPTOMS USING ANTI-CGRP ANTIBODIES, AND COMPOSITIONS AND METHODS RELATED THERETO H LUNDBECK AS (DK) 2026-01-01 US claimed
WO-2025262247-A1 TREATMENT OF HEADACHE DISORDERS AND/OR PSYCHIATRIC SYMPTOMS USING ANTI-CGRP ANTIBODIES, AND COMPOSITIONS AND METHODS RELATED THERETO H. LUNDBECK A/S (DK) 2025-12-26 WO claimed
US-12472146-B2 Extended release pharmaceutical formulation DOUGLAS PHARMACEUTICALS, LTD. (NZ) 2025-11-18 US claimed
EP-4633614-A1 STABLE PHARMACEUTICAL COMPOSITION OF AN AMINE DRUG Sun Pharmaceutical Industries Limited (IN) 2025-10-22 EP claimed
US-12350379-B2 Extended release pharmaceutical formulation and methods of treatment DOUGLAS PHARMACETICALS LTD (NZ) 2025-07-08 US claimed
WO-2025097070-A1 ORAL DOSAGE FORM WITH CATIONICALLY CHARGEABLE HYDROGEL FOR DELIVERY OF ACTIVE AGENT ENTREGA INC. (US) 2025-05-08 WO claimed
US-12263178-B2 Pharmaceutical compositions and methods POP TEST ONCOLOGY LLC (US) 2025-04-01 US claimed
EP-3946296-B9 EXTENDED RELEASE PHARMACEUTICAL FORMULATION DOUGLAS PHARMACEUTICALS LTD (NZ) 2024-12-25 EP claimed
EP-4479032-A1 NEUROACTIVE STEROIDS FOR TREATMENT OF CNS-RELATED DISORDERS Sage Therapeutics, Inc. (US) 2024-12-25 EP claimed
US-4898860-A Anticonvulsant composition and method NEW YORK UNIVERSITY (US) 1990-02-06 US claimed
EP-0174342-B1 BRAIN-SPECIFIC ANALOGUES OF CENTRALLY ACTING AMINES UNIVERSITY OF FLORIDA (US) 1989-12-20 EP claimed
WO-1989005641-A1 DEXTROMETHORPHAN POTENTIATOR FOR ANTICONVULSANT COMPOSITION AND METHOD PONTECORVO MICHAEL J (US) 1989-06-29 WO claimed
EP-0233932-A4 ANTICONVULSANT COMPOSITIONS AND METHOD. UNIV NEW YORK (US) 1988-04-26 EP claimed
EP-0233932-A1 ANTICONVULSANT COMPOSITIONS AND METHOD NEW YORK UNIVERSITY (US) 1987-09-02 EP claimed
EP-0222425-A2 Brain-specific drug delivery UNIVERSITY OF FLORIDA (US) 1987-05-20 EP claimed
EP-0218300-A2 Brain-specific drug delivery UNIVERSITY OF FLORIDA (US) 1987-04-15 EP claimed
WO-1987001036-A1 ANTICONVULSANT COMPOSITIONS AND METHOD NEW YORK UNIVERSITY (US) 1987-02-26 WO claimed
EP-0189861-A2 Percutaneous absorption accelerator for ionic water-soluble medicine SHOWA DENKO KABUSHIKI KAISHA (JP) 1986-08-06 EP claimed
EP-0152379-A2 Process for preparing pharmaceutical compositions containing unilamellar liposomes CIBA-GEIGY AG (CH) 1985-08-21 EP claimed